NemoClaw is NVIDIA’s open source stack for secure AI agents, offering sandboxing, privacy controls, flexible deployment, and efficient runtime management.

A federal judge blocked parts of HHS's vaccine policy changes, siding with medical groups against Robert F. Kennedy Jr.'s agenda.

Novavax (NVAX) closed at $9.62 in the latest trading session, marking a -1.23% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 1.51% for the day. Meanwhile, the Dow ...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, ...

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in ...

There's no easy way to identify the most hated stocks on Wall Street, but looking at the activity of short sellers is a great place to start. Short selling is a difficult art that involves ...

Novavax (NVAX) is back in focus after Q4 2025 results showed surprise profitability, with revenue of US$147.14 million and net income of US$17.53 million, supported by key vaccine partnerships and ...

Novavax reported a fourth-quarter earnings shift to a profit of 11 cents, compared to a loss of 51 cents a year ago, with revenue hitting $147 million, a 67% increase year-over-year. However, the ...

Novavax swings to profit in Q4 CEO remains optimistic despite U.S. regulatory uncertainties Shares surge over 22% after strong results Feb 26 (Reuters) - Novavax (NVAX.O), opens new tab raised its ...

On a per-share basis, the Gaithersburg, Maryland-based company said it had net income of 11 cents. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by ...